Conference Programme

Programme of the “10th Berlin Conference on Life Sciences – Novel Antimicrobials”

Time Title
09:00 – 09:30 Registration
09:30 – 09:45 Welcome address
Nick Leake, Counsellor and Head of the EU & Economic Section at the British Embassy Berlin
Keynote Session
09:45 – 10:10 Keynote: The Global AMR Innovation Fund
Christopher Egerton-Warburton, Fund Manager and Founding Partner of Lion's Head Global Partner and Member of Expert Advisory Bord, Global AMR Innovation Fund
> PPT > CV
10:10 – 10:30 Stimulating innovation: novel approaches to incentivising antibacterial R&D
David Findlay, Deputy Coordinator Drive-AB/GSK, UK
> PPT > CV
10:30 – 10:50 Funding the research and development of novel antibiotics:  the perspective of a startup company
Nicholas Benedict, Co-Founder & CEO, Allecra, GER

> PPT > CV
10:50 – 11:10 Coffee Break
Session "Market access in the era of AMR - bringing ideas to the patients" Session “SMEs to tackle AMR”
Chair: Philippe Villain-Guillot, CEO, Nosopharm


- Leonie de Best, CBO, Madam Therapeutics, NL
> PPT > CV
- Philippe Villain-Guillot, CEO, Nosopharm
> PPT > CV
- Marc Lemonnier, CEO, Antabio, F
> PPT > CV
- Thomas Kapsner, CEO Morphochem, GER
> PPT > CV
11:10 – 11:40 Intellectual Property Rights and their Role in fostering Creation and Distribution of Innovations
Heinz Goddar (Partner), Boehmert & Boehmert, GER
> PPT > CV
Compulsory Licenses – Bliss or Doom for Pharmaceutical Industry
Ute Kilger (Partner), Boehmert & Boehmert, GER
> PPT > CV
11:40 – 12:00 From bench to bedside: Developing new drugs for bad bugs on a European scale
Anders Karlén, University of Uppsala, SE and Managing Coordinator, ENABLE consortium
> PPT > CV
12:00 – 12:20 Clinical decision making: The relevance of new methods for antimicrobial susceptibility testing
Hajo Grundmann, University of Groningen, Member of EUCAST Subcommittee, NL
> PPT > CV
12:20 – 12:50 Panel discussion – How to overcome the bottlenecks in the AMR field?
Christopher Egerton-Warburton, Member of Expert Advisory Bord, Global AMR Innovation Fund 
> CV
Andrew Ullmann, University of Würzburg
> CV
Ute Kilger, Boehmert & Boehmert
> CV
Hajo Grundmann, University of Groningen
> CV
12:50 – 13:40 Lunch Break
Session “How to create a business case with antimicrobials” Session: Think beyond – technology highlights from academic research
Chair: Andrew Ullmann, University of Würzburg


- Yves Briers, Ghent University, BE
> PPT > CV
- Stephan Sieber, Technical University Munich, GER
> CV
- Michael McDonough, University of Oxford, UK
> PPT > CV
- Mark Brönstrup, Helmholtz Centre for Infection Research, GER
> CV
- Andreas Peschel, University of Tübingen, GER
> PPT > CV
13:40 – 14:00 Accelerating the antibiotics pipeline: CARB-X and AMRC 
Peter Jackson, steering group chairman, AMR centre, UK

> PPT > CV
14:00 – 14:20 Reliability of antibiotics supply in Germany –  Effect of supplier consolidation
Morris Hosseini, Roland Berger, GER
> PPT
14:20 – 14:40 The SME perspective 
Marie Petit, Coordinator, BEAM Alliance
Sergio Lociuro, CSO, BioVersys, CH

> PPT > CV1 > CV2
14:40 – 15:40 Technology Highlights
Rasmus Toft-Kehler, CEO, AntibioTx, DK
> PPT > CV
Deborah O’Neil, CEO & CSO, NovaBiotics, UK
> PPT > CV
Frauke Hein, CBO, Adrenomed AG, GER
> PPT > CV
15:40 – 16:10 Coffee Break
Session “Start-up competition & investors talk”
16:10 – 16:40 Investors talk – Panel Discussion: Developing new antimicrobial agents - a business case for start-ups?
Holger Reithinger, Partner, Forbion Capital Partners, GER/NL
Sergio Lociuro, CSO, BioVersys, CH
Rasmus Toft-Kehler, CEO, AntibioTx, DK
Olivier Litzka, Partner, Edmond de Rothschild, F
> CVs
16:40 – 17:20 Start-up pitch: Start-up presentations and award
Auspherix, UK
> PPT > CV
Immunethep, P
> PPT > CV
Juvabis, CH
> PPT > CV
QureTech Bio, S
> PPT > CV
Omnix Medical, ISR
> PPT > CV
17:20 – 17:40 Open discussion and wrap-up: The future of antiinfective R&D
17:40 – 19:00 Networking & reception

Moderator: Peter West, CEO, Academy of Infection Management (AIM)
> CV

Download the conference materials